Meglumine antimoniate: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 20:31, 27 January 2012 edit205.232.183.66 (talk)No edit summary← Previous edit		Latest revision as of 04:45, 20 March 2024 edit undoWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,185 edits →External links: remove section head
(54 intermediate revisions by 35 users not shown)
Line 1:		Line 1:
			{{Short description\|Chemical compound}}
	{{Unreferenced stub\|auto=yes\|date=December 2009}}
	{{Drugbox		{{Drugbox
	\| Verifiedfields = changed		\| Verifiedfields = changed
			\| Watchedfields = changed
	\| verifiedrevid = ~~462102030~~		\| verifiedrevid = 476995406
	\| IUPAC_name = Hydroxy-dioxostiborane; (2''R'',3''R'',4''R'',5''S'')-6-methylaminohexane-1,2,3,4,5-pentol		\| IUPAC_name = Hydroxy-dioxostiborane; (2''R'',3''R'',4''R'',5''S'')-6-methylaminohexane-1,2,3,4,5-pentol
	\| image = Meglumine antimoniate major component 3D.png		\| image = Meglumine antimoniate major component 3D.png

	<!--Clinical data-->		<!--Clinical data-->
			\| synonyms = Meglumine antimonate
	\| tradename =		\| tradename =
	\| Drugs.com = {{drugs.com\|CONS\|meglumine_antimoniate}}		\| Drugs.com = {{drugs.com\|CONS\|meglumine_antimoniate}}
	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->		\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
	\| pregnancy_US = <!-- A / B / C / D / X -->		\| pregnancy_US = <!-- A / B / C / D / X -->
	\| pregnancy_category =		\| pregnancy_category =
	\| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->		\| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
	\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->		\| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
	\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->		\| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->		\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
	\| legal_status =		\| legal_status =
	\| routes_of_administration =		\| routes_of_administration =

	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->
	\| bioavailability =		\| bioavailability =
	\| protein_bound =		\| protein_bound =
	\| metabolism =		\| metabolism =
	\| elimination_half-life =		\| elimination_half-life =
	\| excretion =		\| excretion =

	<!--Identifiers-->		<!--Identifiers-->
	\| CAS_number_Ref = {{cascite\|changed\|??}}		\| CAS_number_Ref = {{cascite\|changed\|??}}
Line 31:		Line 30:
	\| ATC_prefix = P01		\| ATC_prefix = P01
	\| ATC_suffix = CB01		\| ATC_suffix = CB01
	\| ATC_supplemental = {{ATCvet\|P51\|~~AB01~~}}		\| ATC_supplemental = {{ATCvet\|P51\|DX01}}
	\| PubChem = 64953		\| PubChem = 64953
	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}		\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
	\| DrugBank =		\| DrugBank =
	\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}		\| ChemSpiderID_Ref = {{chemspidercite\|correct\|chemspider}}
	\| ChemSpiderID = 58479		\| ChemSpiderID = 58479
Line 40:		Line 39:
	\| ChEMBL = 239129		\| ChEMBL = 239129
	\| NIAID_ChemDB = 008733		\| NIAID_ChemDB = 008733
			\| UNII_Ref = {{fdacite\|changed\|FDA}}
			\| UNII = 75G4TW236W

	<!--Chemical data-->		<!--Chemical data-->
	\| chemical_formula = Variable		\| chemical_formula = Variable

	\| molecular_weight = Variable		\| molecular_weight = Variable
	\| ~~smiles~~ = O=(=O)O.O((O)(O)(O)CNC)CO		\| SMILES = O=(=O)O.O((O)(O)(O)CNC)CO
	\| InChI = 1/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1/rC7H17NO5.HO3Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;1-4(2)3/h4-13H,2-3H2,1H3;(H,1,2,3)/t4-,5+,6+,7+;/m0./s1
	\| InChIKey = XOGYVDXPYVPAAQ-IZBHJHIBBT
	\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}		\| StdInChI_Ref = {{stdinchicite\|correct\|chemspider}}
	\| StdInChI = 1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1		\| StdInChI = 1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1
Line 53:		Line 51:
	\| StdInChIKey = XOGYVDXPYVPAAQ-SESJOKTNSA-M		\| StdInChIKey = XOGYVDXPYVPAAQ-SESJOKTNSA-M
	}}		}}
			<!-- Definition and medical uses -->
	'''Meglumine antimoniate''' (or '''meglumine antimonate''') is a medicine used for treating ]. It is manufactured by ] and sold as '''Glucantime''' in ], and '''Glucantim''' in ]. It belongs to a group of compounds known as the ]s. It is administered by ].
			'''Meglumine antimoniate''' is a medicine used to treat ].<ref name=WHO2008/> This includes visceral, mucocutaneous, and cutaneous leishmaniasis.<ref name=WHO2008/> It is given by ] or into the area infected.<ref name=WHO2008/>

			<!-- Side effects and mechanism -->
			Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, ], and ].<ref name=WHO2008/> It should not be used in people with significant heart, liver, or kidney problems.<ref name=WHO2008/> It is not recommended during ].<ref name=WHO2008/> It belongs to a group of medications known as the ]s.<ref name=WHO2008>{{cite book \| title = WHO Model Formulary 2008 \| year = 2009 \| isbn = 9789241547659 \| vauthors = ((World Health Organization)) \| veditors = Stuart MC, Kouimtzi M, Hill SR \| hdl = 10665/44053 \| author-link = World Health Organization \| publisher = World Health Organization \| hdl-access=free \|page=183 }}</ref>

			<!-- History and culture -->
			Meglumine antimoniate came into medical use in 1946.<ref>{{cite book\| vauthors = Sneader W \| chapter = Chemical Medicines \|title=Drug Discovery: A History\|date=2005\|publisher=John Wiley & Sons\|isbn=9780470015520\|page=59\| chapter-url = https://books.google.com/books?id=jglFsz5EJR8C&pg=PA59\|language=en\|url-status=live\|archiveurl=https://web.archive.org/web/20161220082039/https://books.google.ca/books?id=jglFsz5EJR8C&pg=PA59\|archivedate=2016-12-20}}</ref> It is on the ].<ref name="WHO21st">{{cite book \| vauthors = ((World Health Organization)) \| title = World Health Organization model list of essential medicines: 21st list 2019 \| year = 2019 \| hdl = 10665/325771 \| author-link = World Health Organization \| publisher = World Health Organization \| location = Geneva \| id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO \| hdl-access=free }}</ref> It is available in Southern Europe and ] but not the United States.<ref>{{cite book\| vauthors = Wolfe M \| chapter = Antiparasitic Drugs \| veditors = Bope ET, Kellerman RD, Rakel RE \|title=Conn's Current Therapy 2011: Expert Consult\|date=2010\|publisher=Elsevier Health Sciences\|isbn=978-1437735727\|page=95\| chapter-url=https://books.google.com/books?id=pxnKBrfwTFYC&pg=PT128\|language=en\|url-status=live\|archiveurl=https://web.archive.org/web/20161220082035/https://books.google.ca/books?id=pxnKBrfwTFYC&pg=PT128\|archivedate=2016-12-20}}</ref><ref>{{cite book\| vauthors = Gorbach SL, Bartlett JG, Blacklow NR \|title=Infectious Diseases\|date=2004\|publisher=Lippincott Williams & Wilkins\|isbn=9780781733717\|page=355\|url=https://books.google.com/books?id=91altE1evAsC&pg=PA355\|language=en\|url-status=live\|archiveurl=https://web.archive.org/web/20161220080917/https://books.google.ca/books?id=91altE1evAsC&pg=PA355\|archivedate=2016-12-20}}</ref>

			==Society and culture==
			It is manufactured by ]<ref>{{cite web \| title = Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen \| trans-title = Sanofi-Aventis Reaffirms Its Commitment to Ensuring Access to Medicines in the "Southern Countries" With a Policy of Tiered Drug Prices Depending on Population Income \| language = de \| url = http://www.sanofi.de/l/de/de/layout.jsp?cnt=38A41931-0260-4715-A7C3-25AD268B9C27 \| work = Aventis press release \| archive-url = https://web.archive.org/web/20140522195924/http://www.sanofi.de/l/de/de/layout.jsp?cnt=38A41931-0260-4715-A7C3-25AD268B9C27 \| archive-date=22 May 2014 \| date = 15 April 2005 }}</ref> and sold as Glucantime in ], and Glucantim in ].

	==See also==		==See also==
	* ]		* ]

			==References==
			{{reflist}}

	{{Excavata antiparasitics}}		{{Excavata antiparasitics}}
			{{Portal bar\|Medicine}}

	{{DEFAULTSORT:Meglumine Antimoniate}}		{{DEFAULTSORT:Meglumine Antimoniate}}
	]		]
	]		]
			]

			]

	{{antiinfective-drug-stub}}

Latest revision as of 04:45, 20 March 2024

Chemical compound Pharmaceutical compound

Meglumine antimoniate
Clinical data

Other names	Meglumine antimonate
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	P01CB01 (WHO) QP51DX01 (WHO)
Identifiers
IUPAC name Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
CAS Number	133-51-7
PubChem CID	64953
ChemSpider	58479
UNII	75G4TW236W
ChEMBL	ChEMBL239129
NIAID ChemDB	008733
CompTox Dashboard (EPA)	DTXSID4043935
ECHA InfoCard	100.004.645
Chemical and physical data
Formula	Variable
Molar mass	Variable
3D model (JSmol)	Interactive image
SMILES O=(=O)O.O((O)(O)(O)CNC)CO
InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M
(what is this?) (verify)

Meglumine antimoniate is a medicine used to treat leishmaniasis. This includes visceral, mucocutaneous, and cutaneous leishmaniasis. It is given by injection into a muscle or into the area infected.

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems. It should not be used in people with significant heart, liver, or kidney problems. It is not recommended during breastfeeding. It belongs to a group of medications known as the pentavalent antimonials.

Meglumine antimoniate came into medical use in 1946. It is on the World Health Organization's List of Essential Medicines. It is available in Southern Europe and Latin America but not the United States.

Society and culture

It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy.

References

^ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
Sneader W (2005). "Chemical Medicines". Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Wolfe M (2010). "Antiparasitic Drugs". In Bope ET, Kellerman RD, Rakel RE (eds.). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 978-1437735727. Archived from the original on 2016-12-20.
Gorbach SL, Bartlett JG, Blacklow NR (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
"Sanofi-Aventis Bekräftigt Seine Verpflichtung Zur Sicherstellung Des Zugangs Zu Medikamenten in Den "Südlichen Ländern" Mit Einer Politik Der Gestaffelten Arzneimittelpreise Je Nach Bevölkerungseinkommen" [Sanofi-Aventis Reaffirms Its Commitment to Ensuring Access to Medicines in the "Southern Countries" With a Policy of Tiered Drug Prices Depending on Population Income]. Aventis press release (in German). 15 April 2005. Archived from the original on 22 May 2014.

Antiparasitics directed at excavata parasites (P01)

Discicristata

Trypanosomiasis

African trypanosomiasis	ornithine (Eflornithine) arsenical (Atoxyl, Melarsoprol, Tryparsamide) benzamidine (Pentamidine) naphthalenesulfonate (Suramin) nitroimidazole (Fexinidazole)
Chagas disease	nitroimidazole (Benznidazole) nitrofuran (Nifurtimox)